National Academies Press: OpenBook

Animal Models for Assessing Countermeasures to Bioterrorism Agents (2011)

Chapter: Appendix E: Statement of Task

« Previous: Appendix D: Presentations to the Committee
Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×

Appendix E

Statement of Task Animal Models for Assessing Countermeasures to Bioterrorism Agents

Summary

The National Academies will convene an ad hoc committee to examine the utility and relevance of animal models to Transformational Medical Technologies Initiative (TMTI)-funded research. The report will: 1) Evaluate how well the existing TMTI-employed or candidate animal models reflect human disease as related to the agents of interest; 2) Address the process and/or feasibility of developing new animal models for critical biodefense research, placing emphasis on the need for a robust and expeditious validation process in terms of the U.S. Food and Drug Administration’s (FDA’s) Animal Rule; 3) Evaluate alternatives to the use of animal models based on the premise of The Three Rs vis-à-vis the Animal Rule and FDA licensure. The evaluation will also consider the development of more humane models for infectious diseases research that do not incorporate death as an endpoint (i.e., humane endpoints).

Policy Context

A major component of the U.S. Department of Defense (DoD) efforts in biodefense is the Transformational Medical Technologies Initiative (TMTI), the goal of which is to protect warfighters from disease and biological warfare agents. Specifically, the rationale of the Initiative is to fully exploit advanced science and technology innovation in order to successfully counter future genetically engineered biological weapons and naturally emerging infectious diseases that can impact the warfighter.

In the past DoD has had a significant focus on the production of individual vaccines for diseases such as anthrax, smallpox, and plague. TMTI seeks to expand that focus to facilitate basic and applied research that will lead to the development of broad-spectrum countermeasures (preventative, prophylactic and therapeutic) that could provide multivalent solutions (for example, one drug that would offer protection from multiple types of pathogens) against advanced bio-terror threats. TMTI is

Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×

therefore funding basic and applied research designed to advance the development of such countermeasures.

There are several challenges to developing such countermeasures under each of the TMTI’s Current Thrust Areas (i.e., host immune enhancement; genomic identification; nucleotide therapeutics; protein based therapeutics/biologics; small molecule/drugs; metabolomics). One area of particular concern is the need to develop countermeasures for diseases that are not endemic in the United States or in other developed countries and for which no reliable treatment exists. Further, countermeasures are called for to deal with unnatural diseases resulting from bioterrorism or biowarfare. Another potential concern with countermeasures-related research is that it is conceivable that some of its results could be used by terrorists to advance offensive biowarfare.

According to Department of Defense Instruction Number 6200.02 of February 27, 20081 , “personnel carrying out military operations shall be provided the best possible medical countermeasures to chemical, biological, or radiological warfare or terrorism and other health threats. The DoD Components shall make preferential use of products approved by the Food and Drug Administration (FDA) for general commercial marketing, when available, to provide the needed medical countermeasure.” Therefore high priority is given to work that will facilitate FDA approval of new countermeasures developed through TMTI. Lack of scientific expertise and available information necessitates that such countermeasures research is based on experimental animal models.

Ethical constraints preclude the use of human participants in efficacy studies that could kill or permanently disable healthy human volunteers. In order to overcome this predicament, FDA promulgated the Animal Rule (21 CFR Parts 314 and 601). It is expected that many TMTI-developed products would be submitted to FDA and subject to evaluation under the Animal Rule.

Technical Context

Biomedical research depends on the use of animals in order to understand how human and non-human organisms function. Investigators use animals to understand the continuum between basic mechanisms in a single cell (e.g., enzymatic properties, gene influences) and the health and disease of the whole organism. In fact, the use of animals as working representations for a variety of human conditions offers an alternative to the use of human participants. However, in order for these models to be useful correlates, they should be reproducible and verifiable (i.e., offer proof of concept) and reliably predict the safety and efficacy of clinical trials. Animal models as surrogates for humans have mixed success. In some cases, the animals correctly model the processes occurring in humans; in others, there are similarities between the animal models and humans, but the two are not exact. Furthermore, when modeling an unknown or minimally understood process, it is difficult at the outset to determine which animal model would best approximate the human situation.

In the case of the Animal Rule, FDA allows the substitution of appropriate studies in animals as “evidence of the effectiveness of new drugs or biologicals when adequate or well-controlled clinical studies in humans cannot be ethically conducted” (the Animal Rule; 21 CFR Parts 314 and 601). Licensing the medical countermeasures mandated by TMTI under the Animal Rule is challenging due to a number of concerns. FDA approval under the Animal Rule requires validated animal models that predict the efficacy of new drugs or biologicals in humans. This relatively new approach to attaining full licensure for drugs and biologicals presents new and unique challenges such as establishing validated animal models that meet FDA requirements, working in compliance with Good Laboratory Practice (GLP) regulations in a high-containment environment, and meeting the obligation to continuously identify refinements in the field of infectious disease research in general.

_________________________

1 Department of Defense Instruction Number 6200.02; www.dtic.mil/whs/directives/corres/pdf/620002p.pdf

Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×

As stated above, it would be unethical to test these agents in humans; therefore it is essential to choose the correct animal model for investigating countermeasures to bioterrorism agents. In some cases, there may be enough information about the pathophysiology of the agent and the intervention to enable a quick and accurate determination of the appropriate model. In other cases, it may be necessary to glean information from multiple models or to use other, newly emerging non-animal methods to establish a baseline understanding of the agent(s) involved. Such new methods are coming into greater use as their applications to the study of drug efficacy and drug and chemical toxicity are being delineated. In this project, it will be necessary for the committee to consider these and other possibilities for the study of countermeasures to bioterrorism agents in making recommendations to the Department of Defense.

Statement of Task

A major component of the U.S. Department of Defense (DoD) efforts in biodefense is the Transformational Medical Technologies Initiative (TMTI), the goal of which is to protect warfighters from disease and biological warfare agents. Specifically, the rationale of the Initiative is to fully exploit advanced science and technology innovation in order to successfully counter future genetically engineered biological weapons and naturally emerging infectious diseases that can impact the warfighter.

Ethical constraints preclude the use of human participants in efficacy studies that could kill or permanently disable healthy human volunteers. In order to overcome this predicament, the U.S. Food and Drug Administration (FDA) instigated the Animal Rule (21 CFR Parts 314 and 601). It is expected that many TMTI-developed products would be submitted to FDA and subject to evaluation under the Animal Rule.

The National Academies will convene an ad hoc committee to examine the utility and relevance of animal models to TMTI-funded research and prepare a consensus report. Specifically, the committee’s report will:

1. Evaluate how well the existing TMTI-employed or candidate animal models reflect the pathophysiology, clinical picture and treatment of human disease as related to the agents of interest.

2. Address the process and/or feasibility of developing new animal models for critical biodefense research, placing emphasis on the need for a robust and expeditious validation process in terms of FDA’s Animal Rule.

3. Evaluate alternatives to the use of animal models based on the premise of The Three Rs (i.e., refinement, reduction, and replacement of animal use; such venues would include but not be limited to in vitro work, computational modeling, new biotechnological tools, surrogate diseases, etc.) vis-à-vis the Animal Rule and FDA licensure. The evaluation will also consider the development of more humane models for infectious diseases research that do not incorporate death as an endpoint (i.e., humane endpoints).

Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×

This page intentionally left blank.

Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×
Page 127
Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×
Page 128
Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×
Page 129
Suggested Citation:"Appendix E: Statement of Task." National Research Council. 2011. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press. doi: 10.17226/13233.
×
Page 130
Next: Appendix F: About the Authors »
Animal Models for Assessing Countermeasures to Bioterrorism Agents Get This Book
×
Buy Paperback | $46.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The Transformational Medical Technologies (TMT) has been a unique component of the U.S. Department of Defense (DoD) medical biodefense efforts since 2006. Its mission is to advance countermeasure research and development in support of the broader goal of the DoD to protect warfighters from emerging infectious diseases and future genetically engineered biological weapons. The TMT, using advanced science and technology approaches, focused on the development of roadspectrum countermeasures that target common host and pathogen pathways or enhance the host's immune response. Many of these pathogens are lethal or cause such debilitating diseases in humans that it is ethically inappropriate to test the efficacy of these countermeasures in human volunteers. In lieu of human participants, these products may be tested in animals and approved for human use under the provisions of the Food and Drug Administration (FDA)'s 2002 Animal Rule. The reliance on animal models for the development and licensure of medical countermeasures against biothreats is challenging for a number of reasons.

The ad hoc Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents prepared a consensus report that would address the challenges stemming from developing and testing medical countermeasures against biothreat agents in animal models. Animal Models for Assessing Countermeasures to Bioterrorism Agents evaluates how well the existing TMT-employed or candidate animal models reflect the pathophysiology, clinical picture, and treatment of human disease as related to the agents of interest. The report addresses the process and/or feasibility of developing new animal models for critical biodefense research, placing emphasis on the need for a robust and expeditious validation process in terms of the FDA's Animal Rule. The report also evaluates alternatives to the use of animal models based on the premise of the Three Rs.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!